ARMISTICE CAPITAL, LLC
Top Portfolio Positions
229 positions ·
$4,773,613,555 total
· as of Mar 31, 2026
| Ticker | Company | Shares | Value (USD) | % of Portfolio | Open |
|---|---|---|---|---|---|
| SPY |
Spdr S&P 500 ETF Trust
|
2,100,000 | $1,365,714,000 | 28.61% | |
| AGIO |
Agios Pharmaceuticals, Inc.
Healthcare
|
5,916,000 | $200,138,280 | 4.19% | |
| CYTK |
Cytokinetics Inc
Healthcare
|
2,664,538 | $175,619,699 | 3.68% | |
| PTCT |
Ptc Therapeutics, Inc.
Healthcare
|
2,464,449 | $167,902,910 | 3.52% | |
| TVTX |
Travere Therapeutics, Inc.
Healthcare
|
4,897,417 | $145,502,259 | 3.05% | |
| MDGL |
Madrigal Pharmaceuticals, Inc.
Healthcare
|
264,583 | $138,501,263 | 2.90% | |
| IMVT |
Immunovant, Inc.
Healthcare
|
5,464,916 | $135,748,513 | 2.84% | |
| SUPN |
Supernus Pharmaceuticals, Inc.
Healthcare
|
1,895,347 | $97,970,486 | 2.05% | |
| NBIX |
Neurocrine Biosciences Inc
Healthcare
|
724,000 | $95,379,760 | 2.00% | |
| RIGL |
Rigel Pharmaceuticals Inc
Healthcare
|
2,560,000 | $69,222,400 | 1.45% |
Portfolio Trend
25 quarters · across all stocks
Holdings in TMCI
Shares Held
Position Value (USD)
10 quarters on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $8,527,760 | 6,364,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $15,591,800 | 6,364,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $42,380,360 | 6,316,000 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $36,808,800 | 6,260,000 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $52,110,290 | 6,211,000 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $46,194,960 | 6,209,000 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $35,936,800 | 6,196,000 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $35,644,000 | 5,360,000 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $31,320,000 | 2,400,000 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $36,414,000 | 2,856,000 | Shares | Sole | 2024-02-13 | |
| No 13F history on record for this holder in this stock. | ||||||